Dedifferentiated liposarcoma: Life with an ultra rare cancer Dedifferentiated liposarcoma: Life with an ultra rare cancer For Dan, being diagnosed with dedifferentiated liposarcoma, an ultra rare sarcoma, was life changing, and means he now makes the most of every day.
Facing lung cancer Facing lung cancer Keith and Heather talk about their experiences of facing lung cancer as a family and finding purpose after treatment.
New digital Tx collab with Click New digital Tx collab with Click New digital therapy collaboration with Click Tx
The impact of carbon reduction projects The impact of carbon reduction projects Boehringer Ingelheim voluntarily contributes to carbon reduction projects that benefit sustainable development.
Boehringer Ingelheim collaborates with Circle Pharma Boehringer Ingelheim collaborates with Circle Pharma Boehringer Ingelheim collaborates with Circle Pharma to develop a first-in-class cyclin RxL inhibitor that can halt the growth of cancer cells
discontinuation-bi-1467335-diabetic-retinopathy discontinuation-bi-1467335-diabetic-retinopathy The discontinuation of the development of BI 1467335 in diabetic retinopathy has been announced
2024 half year results innovation progress 2024 half year results innovation progress First half of 2024: Boehringer Ingelheim progresses pipeline at pace and reaches major milestones
Our culture Our culture Our culture reflects who we are and is reflected in Our FOCUS and strong belief in Diversity, Equity and Inclusion as well as Sustainable Development.
EMPRISE-interim-analysis EMPRISE-interim-analysis Interim analysis from EMPRISE real-world study shows decreased risk of hospitalisation for heart failure compared with DPP-4 inhibitors and GLP-1 receptor agonists
preserved-heart-failure-treatment-FDA-US-approval preserved-heart-failure-treatment-FDA-US-approval US FDA approves Jardiance® (empagliflozin) to treat adults with heart failure regardless of left ventricular ejection fraction
DCRI-collaboration-empact-mi DCRI-collaboration-empact-mi Collaboration with Duke Clinical Research Institute on EMPACT-MI trial, which will assess outcomes in people who have had a myocardial infarction
Diabetes dog symptoms chronic disease management Diabetes dog symptoms chronic disease management Learn about the symptoms of canine diabetes and how to manage the disease.
Improving lives by providing better access to treatments Improving lives by providing better access to treatments Our ‘Access to Healthcare’ initiative aims to extend support to underserved communities affected by Non-Communicable Diseases
REACH / GHS / Material safety data sheets REACH / GHS / Material safety data sheets We are continuously working on these topics with the aim to be in compliance with requirements deriving from these legislations.
Boosting performance with an inclusive performance culture Boosting performance with an inclusive performance culture Boosting performance of organizations with an inclusive performance culture
founding-member-of-QUTAC founding-member-of-QUTAC Together, the members of this newly founded consortium want to explore industrial applications for quantum computing
Financial health Financial health We constantly review our salaries to make sure they stay competitive in each market but we also provide wider support for financial health.
Learning and development Learning and development We help people grow professionally by maximizing our talent and giving them room to evolve within the company.
Smart scanners to spot fleas and ticks on your pet Smart scanners to spot fleas and ticks on your pet How to identify fleas and ticks? With technology, vets can now spot pet parasites with high-definition videos in real time.
What do you know about transboundary animal diseases What do you know about transboundary animal diseases Transboundary animal diseases (TADs) are highly transmissible diseases of livestock that can impact veterinary public health preparedness.
Are combination therapies the answer to battling KRAS cancers? Are combination therapies the answer to battling KRAS cancers? Dr Ulrich Dünzinger and Kristie Fernamberg talk about their work with the SOS1 KRAS inhibitor to block tumour-triggering signal
The big, the bold, and the few The big, the bold, and the few In the animal health industry, fewer players are vying for bigger market shares. What does that mean for companies, veterinarians, and consumers?
Breakthrough-Therapy-Designation-Progressive-Fibrosing-ILD Breakthrough-Therapy-Designation-Progressive-Fibrosing-ILD FDA Grants nintedanib Breakthrough Therapy Designation for Chronic Fibrosing ILDs with a Progressive Phenotype